Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT06349486
Recruiting Not applicable

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication

NCT06349486 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Kaohsiung Medical University
Phase
Not applicable
Started
2023-11-28
Last updated
2026-01-15

Condition(s) studied

Helicobacter Pylori Eradication

Investigational drug(s) / intervention(s)

vonoprazan, amoxicillin, tripotassium dicitrate bismuthatevonoprazan, amoxicillinrabeprazole, amoxicillin, clarithromycin

vonoprazan, amoxicillin, tripotassium dicitrate bismuthate: bismuth-amoxicillin-vonoprazan triple therapy

vonoprazan, amoxicillin: vonoprazan-amoxicillin dual therapy

rabeprazole, amoxicillin, clarithromycin: proton pump inhibitor-based standard triple therapy

Study summary

1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection.
2. To investigate the impacts of antibiotic resistance of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H. pylori treatments.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: (1) At least 18 years old. (2) Subjects infected with Helicobacter pylori. Exclusion Criteria: 1. Those who have ever received Helicobacter pylori sterilization treatment. 2. Those who are allergic to the drugs used in this research. 3. Those who have had stomach surgery. 4. Those with severe liver cirrhosis or uremia or malignant tumors. 5. Women who are pregnant or breastfeeding.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Kaohsiung Medical University Hospital Kaohsiung City Taiwan Recruiting

More Kaohsiung Medical University trials in Taiwan

Acute Effects of Progressive Muscle Relaxation on Brain Waves Recruiting
Effectiveness of an Online Interactive E-book in Enhancing Home Care Nurses' Knowledge, Perceived Barriers, and Self-efficacy in Home Pressure Injury Care Recruiting
Blood Flow Restriction Parameters and Lower Limb Function in Older Adults With Dynapenia Starting soon
Leg Press Power Training with Visual Feedback Games Improves Physical, Cognitive, and Heart Health in Seniors Active, not recruiting
Neck Integration and Eye Movement Training for Fall Risk in the Elderly Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06349486 on ClinicalTrials.gov ↗ ← All trials in Taiwan